Malawi
Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country**: Malawi

2. **Grant number**: 1820-MWI-12d-X / 10-MWI-08b-Y/17-MWI-25a-Y

3. **Date of Decision Letter**: 23 March 2018

4. **Date of the Partnership Framework Agreement**: 22 October 2014

5. **Programme title**: New Vaccine Support (NVS), Pneumococcal Routine

6. **Vaccine type**: Pneumococcal

7. **Requested product presentation and formulation of vaccine**: PCV13, 4 doses/vial, liq

8. **Programme duration**: 2011-2020

9. **Programme Budget (indicative)**: (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Year</th>
<th>2011-2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>63,517,022³</td>
<td>4,352,500</td>
<td>7,417,000</td>
<td>8,073,500</td>
<td>83,360,022</td>
</tr>
</tbody>
</table>

10. **Vaccine introduction grant/ Product Switch grant (in US$)**: A ViG of US$223,000 was disbursed on 27/4/2011. A Product Switch Grant of US$ $182,289 was disbursed on 7/6/2017

11. **Indicative Annual Amounts**: (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2011-2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Pneumococcal vaccines doses</td>
<td></td>
<td>1,296,400</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$63,517,022⁵</td>
<td>US$4,352,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency**: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. **Self-procurement**: Not applicable

---

¹ This is the entire duration of the Programme.
² This is the total amount endorsed by Gavi for the entire duration of the Programme.
³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
⁴ This is the amount that Gavi has approved.
⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>90,400</td>
<td>148,000</td>
<td>155,400</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>US$275,696</td>
<td>US$451,118</td>
<td>US$473,662</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>US$277,500</td>
<td>US$454,000</td>
<td>US$477,000</td>
</tr>
</tbody>
</table>

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information | Due dates
---|---
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,
On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
23 March 2018